CLEVELAND, Sept. 16, 2019 /PRNewswire/ -- ViewRay, Inc.
(NASDAQ: VRAY) announced today that Penn State Health has entered
into a master agreement for the purchase of up to four MRIdian
systems, placing an order for its first system today. Penn State
Health, which includes the Milton S. Hershey Medical Center and St.
Joseph Medical Center, has selected MRIdian to offer personalized,
precise radiation therapy in its community centers, delivering
world-class care to the patients it serves.
MRIdian integrates MRI technology, radiation delivery, and
proprietary software to locate, target, and track the position and
shape of soft-tissue and tumors while radiation is delivered. These
capabilities allow MRIdian to deliver accurate doses of radiation
to the tumor while protecting nearby healthy tissues and vulnerable
structures, enabling personalized, non-invasive cancer treatment.
The use of MRIdian is associated with improved patient outcomes,
shorter treatment durations, and reduced treatment-related side
effects.
Penn State Health is a nationally ranked premier health care
provider on the east coast and a world-leading medical research
institution. Penn State Health approaches cancer treatment with a
comprehensive, integrated program focused on education and
prevention, early detection and diagnosis, and effective treatment
and survivorship programs.
"We are here to ensure each cancer patient receives the right
diagnosis and the right therapy at the right time," said Dr.
Rodney Ellis, Chair of the
Department of Radiation Oncology at Penn State Health. "The MRIdian
allows us to see – for the first time – what's happening inside the
body during treatment. Our clinicians will offer personalized
radiotherapy with real-time treatment adaptations, staying true to
our mission: to offer the best possible care for our patients, in a
community setting."
"The introduction of MRIdian technology at Penn State Health is
a testament to the compelling clinical and economic benefits that
MRIdian enables," said Scott Drake, the President and CEO
of ViewRay. "We are proud to partner with Penn State Health to
improve cancer care and access for patients."
About Penn State Health
Penn State Health is a multi-hospital health system serving
patients and communities across 29 counties in central Pennsylvania. It employs more than 14,000
people systemwide. The system includes Penn State Health Milton S.
Hershey Medical Center, Penn State Children's Hospital, and Penn
State Cancer Institute based in Hershey, Pa.; Penn State Health St. Joseph
Medical Center in Reading, Pa.;
and more than 2,000 physicians and direct care providers at more
than 100 medical office locations. Additionally, the system jointly
operates various health care providers, including Penn State Health
Rehabilitation Hospital, Hershey Outpatient Surgery Center, Hershey
Endoscopy Center, Horizon Home Healthcare and Pennsylvania
Psychiatric Institute. In December
2017, Penn State Health partnered with Highmark Health to
facilitate creation of a value-based, community care network in the
region. Penn State Health shares an integrated strategic plan and
operations with Penn State College of
Medicine, the University's medical school.
About ViewRay
ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures,
and markets the MRIdian radiation therapy system. MRIdian is built
upon a proprietary high-definition MR imaging system designed from
the ground up to address the unique challenges and clinical
workflow for advanced radiation oncology. Unlike MR systems used in
diagnostic radiology, MRIdian's high-definition MR was purposely
built to deliver high-precision radiation without
unnecessary beam distortion, and consequently, help to
mitigate skin toxicity and other safety concerns that may otherwise
arise when high magnetic fields interact with radiation beams.
ViewRay and MRIdian are registered trademarks of ViewRay,
Inc.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/penn-state-health-enters-into-master-purchase-agreement-with-viewray-for-mridian-systems-300918379.html
SOURCE ViewRay, Inc.